This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Song, J. Articles by Chiu, R. Search for Related Content PubMed PubMed Citation Articles by Song, J. Articles by Chiu, R.

Gene Silencing in Androgen-Responsive Prostate Cancer Cells from the Tissue-Specific Prostate-Specific Antigen Promoter

¹ Dental Research Institute, University of California Los Angeles (UCLA) School of Dentistry, ² Department of Surgery/Oncology, UCLA School of Medicine, and ³ Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and ⁴ BioResource Center, RIKEN, Ibaraki, Japan

The success of gene therapy using a RNA interference approach relies on small interfering RNA (siRNA) expression from a highly tissue-specific RNA polymerase II promoter rather than from ubiquitous RNA polymerase III. Accordingly, we have developed a prostate-specific vector that expresses siRNAs from the human prostate-specific antigen promoter, a RNA polymerase II promoter. Our data demonstrate androgen-dependent and tissue-specific siRNA-mediated gene silencing in the androgen-responsive prostate cancer cell line, LNCaP. The biological significance was evidenced by altered apoptotic activity through the inhibition of the apoptosis-related regulatory gene. These results demonstrate that siRNA-mediated gene silencing from a tissue-specific RNA polymerase II promoter could be a potential tool for tissue-specific gene therapy.

This article has been cited by other articles:

				R. L. Juliano, V. R. Dixit, H. Kang, T. Y. Kim, Y. Miyamoto, and D. Xu Epigenetic manipulation of gene expression: a toolkit for cell biologists J. Cell Biol., June 20, 2005; 169(6): 847 - 857. [Abstract] [Full Text] [PDF]